Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Benecchi

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Oncology|August 1, 2012
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease?Gianluigi Taverna, Luigi Benecchi, Fabio Grizzi, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|April 17, 2020
Comprehensive long-term assessment of outcomes following robot-assisted partial nephrectomy for renal cell carcinoma: the ROMe's achievement and its predicting nomogramAldo Brassetti, Umberto Anceschi, Riccardo Bertolo, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Oncology|August 1, 2012
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease?Gianluigi Taverna, Luigi Benecchi, Fabio Grizzi, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|April 17, 2020
Comprehensive long-term assessment of outcomes following robot-assisted partial nephrectomy for renal cell carcinoma: the ROMe's achievement and its predicting nomogramAldo Brassetti, Umberto Anceschi, Riccardo Bertolo, et al.
Pageof 2